Events

Careers with impact: working in ML applied drug discovery

One of the unexpected outcomes of the COVID-19 pandemic has been that it has made technology talent aware of the opportunities to use technology to tackle some of the world’s most important and pressing healthcare challenges. 


4th November 2020 | 5.30pm UK time - 12:30pm NYC Time

While interest in joining the industry has increased, many are prevented from taking the leap due to a belief that they do not possess the necessary scientific knowledge. This invisible door is preventing talented people from entering the industry. Worryingly, this problem could be amplified for women in tech, who are already less likely to apply for a role they’re not 100% qualified for.

This meetup will look to demystify AI in drug discovery in order to empower female tech talent to take the leap into this important growth industry. We will counter preconceptions that only those with scientific knowledge can join, by showcasing how we work at BenevolentAI, where we bring together cross-functional teams of machine learning engineers, AI scientists, data scientists and informaticians to co-create our AI platform for drug discovery, alongside our seasoned drug discoverers.

This is a free event and we’d love you to join us for an evening of open dialogue and ideas exchange. 

→ Register here

Event agenda

17:30 – Grab a drink of your choice, get comfy and logon for an intro from Sam

17:35 – 19:55 – Panel discussion part I: countering preconceptions that only those with scientific knowledge can join the drug discovery industry

17:55 - 18:15 – Panel discussion part II: exploring the importance of diverse skills and experiences in AI applied drug discovery, and discussing practical actions to building diverse and inclusive teams.

18:15 - 18:20 – Q&As

18:20 - 18:50 – Split into virtual rooms for networking and a Q&A opportunity with the Benevolent team.


Speakers:

Ana Leite | Lead Bioinformatic Data Scientist

Aylin Cakiroglu | Senior AI Scientist

Paidi Creed | Director, AI Science

Saee Paliwal | Lead AI Scientist

Sam Coulter (Moderator) | Talent Acquisition Specialist


More Posts

You Might Also Like

News
BenevolentAI announces participation in upcoming investor conferences
BenevolentAI announces its participation at two upcoming biotech and healthcare investor conferences hosted by Goldman Sachs and Morgan Stanley.
Jun 10, 2022
News
BenevolentAI Announces Board Changes
BenevolentAI today announces the appointment of Dr. Susan Liautaud as a member of the board of directors of the Company with effect from 30 June 2022. Dr. Susan Liautaud will act as Independent Non-Executive Director of the Company.
May 25, 2022
News
BenevolentAI achieves third milestone in its AI-enabled drug discovery collaboration with AstraZeneca
AstraZeneca selects another novel target for idiopathic pulmonary fibrosis from the collaboration for its drug development portfolio.
May 17, 2022
Blog
FDA converts emergency approval of baricitinib — first identified as a COVID treatment by BenevolentAI — to a full approval
The FDA has converted its emergency approval of baricitinib to a full approval, underscoring the strength of BenevolentAI’s AI-derived hypothesis.
May 12, 2022
News
BenevolentAI Begins Trading On Euronext Amsterdam
BenevolentAI, a leading, clinical-stage AI-enabled drug discovery company, announces that trading in its shares is expected to begin today, following completion of its business combination with Odyssey Acquisition S.A. on 22 April 2022.
Apr 25, 2022
Video
BenevolentAI · AI-Enabled Drug Discovery
Advanced technologies, combined with an exponential increase in biomedical data and research, provide an unparalleled opportunity to unravel the mysteries of diseases that have gone untreated for too long.
Apr 25, 2022